Institute of Stem Cell and Translational Cancer Research

Purpose
To garner a better understanding of stem cells and cancer, and to translate basic research into regenerative medicine and novel anticancer therapies via team work and various platforms for clinical applications

從事有關幹細胞與癌症的研究，藉由整合跨領域研究題材，積極與臨床醫師合作進行轉譯研究。發展宏觀、破壞性創新與實質影響的生醫研究，具體改善醫療與健康

Introduction of ISCTCR
The Institute of Stem Cell and Translational Cancer Research (ISCTCR) was established in Dec 2013 and is located in the 5J of Chang Gung Memorial Hospital (CGMH), Linkou. ISCTCR are organized by two Distinguished Chair Professors, John Yu, M.D., Ph.D. and Alice Yu, M.D., Ph.D. who are outstanding scientists in stem cell biology and translational cancer research, respectively. This Institute has assembled a team of investigators who have expertise complementary to each other and conducive for a cohesive, interrelated team work, in order to garner a better understanding of stem cells and cancer, and translate to regenerative medicine and cancer therapy. The Institute also uses innovative technology platforms such as glycomics/glycoproteomics, phosphoproteomics, high sensitivity liquid chromato-graphy-mass spectrometry, and state of the art tumor immunology, to facilitate interdisciplinary and collaborative research for the identification of unique markers and regulators for stem cells and cancer including cancer stem cells (CSCs). By integrating scientific discoveries with clinical resources of CGMH at Linkou, ISCTCR aims to develop new diagnostic tools and novel therapeutic strategies for cancer with a future perspective to play a more critical role in the development of biomedical research and industry in Taiwan.